how to not regain weight after semaglutide TrimRX Many Patients Maintain Weight Loss

[6] Phase III ACHIEVE-1 trial [edit] In April 2025, results from a phase III clinical trial involving 559 people with type 2 diabetes who took an oral orforglipron pill or a placebo daily for 40 weeks showed that orforglipron produced a reduction of hemoglobin A1C level by 1.3 to 1.6 percentage points from a starting level of 8%

Reduced Inflammation Chronic inflammation is linked to numerous diseases

If you only took it once weekly, levels would drop too low between doses to remain effective

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (surpass-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 surpass-3 trial